Diabetic status modifies the impact of an NAFLD-associated single nucleotide polymorphism

Diabetic status modifies the impact of an NAFLD-associated SNP

Context is known to influence many spheres. And now, researchers from Japan have found that a patients’ health context—that is, the other conditions a patient has—can determine whether a specific gene mutation is helpful or harmful. Researchers from Tokyo Medical and Dental University (TMDU) and Cincinnati Children’s Hospital Medical Center (CCHMC) have revealed that a genetic mutation with a controversial connection to liver disease confers different levels of risk depending on whether patients have diabetes.

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease, and can develop into nonalcoholic steatohepatitis (NASH) involving fat accumulation, damage, and inflammation in the liver. Known genetic variants explain only a modest fraction of the risk of developing NAFLD/NASH, and researchers disagree on the importance of certain mutations.

“The association of the glucokinase regulatory protein (GCKR)-rs1260326 mutation with NAFLD is widely debated,” says first author Masaki Kimura at CCHMC. “This mutation appears to protect patients from diabetes and chronic kidney disease, but is associated with an increased risk of NAFLD and other diseases.”

To better understand the role of GCKR-rs1260326 in NAFLD/NASH, cells were taken from 24 donors and grown into tiny liver-like organs, called organoids. Feeding them extra fatty acids resulted in fat accumulation, inflammation, and insulin resistance, traits that are seen in the livers of patients with NASH. The connections between genetic variants and liver organoid features were then closely analyzed.

“The results were very clear,” states Takanori Takebe, senior author. “We found that the NAFLD/NASH risk connected to the GCKR-rs1260326 mutation in our organoid model was very high, despite it rarely being considered to be clinically significant.”

Organoids with two copies of the GCKR-rs1260326 mutation took up fat from their environment much more efficiently than other organoids, which explains how this mutation could make patients develop a fatty liver.

Unexpectedly, analysis of real-life patient data showed that the level of liver inflammation in NASH patients with diabetes differed based on the presence or absence of the mutation: diabetic patients with two copies of the mutation had high levels of liver inflammation, while diabetic patients with no copies of the mutated gene showed only low levels of inflammation.

Furthermore, the researchers found that treating patients with metformin, a drug commonly used for diabetes, only worked when patients carried unmutated copies of GCKR. However, combined treatment with the drugs nicotinamide riboside and nitozoxanide improved the function of the liver organoids with two copies of the GCKR-rs1260326 mutation.

“This finding suggests a new treatment approach that could make a real impact in the lives of diabetic patients with the mutation who do not respond to standard medication,” states Kimura.

With NAFLD affecting nearly one billion people globally, early identification of patients who need different types of care may improve NASH prevention and treatment. In addition, this study shows that studying organoids ‘”in a dish'” and combining this information with clinical data can offer rich insight into complex, common diseases.

The article was published in Cell.

More information:
Masaki Kimura et al, En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH, Cell (2022). DOI: 10.1016/j.cell.2022.09.031

Journal information:

Source: Read Full Article